Viking Therapeutics Inc.

30.23
-2.33 (-7.16%)
At close: Feb 10, 2025, 3:59 PM
30.28
0.17%
After-hours Feb 10, 2025, 07:59 PM EST
undefined%
Bid 30.23
Market Cap 3.37B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.01
PE Ratio (ttm) -29.93
Forward PE n/a
Analyst Buy
Ask 30.28
Volume 5,004,973
Avg. Volume (20D) 3,995,431
Open 32.74
Previous Close 32.56
Day's Range 29.91 - 32.74
52-Week Range 29.82 - 99.41
Beta undefined

About VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also deve...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 28, 2015
Employees 30
Stock Exchange NASDAQ
Ticker Symbol VKTX

Analyst Forecast

According to 13 analyst ratings, the average rating for VKTX stock is "Buy." The 12-month stock price forecast is $102, which is an increase of 237.44% from the latest price.

Buy 92.31%
Hold 7.69%
Sell 0.00%
Stock Forecasts
19 hours ago
-7.34%
Viking Therapeutics shares are trading lower after... Unlock content with Pro Subscription
5 days ago
-6.09%
Viking Therapeutics shares are trading lower after Piper Sandler cut its price target on the stock from $74 to $71.